Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/14/2024 | Buy → Neutral | Guggenheim | |
3/14/2024 | $9.00 → $2.00 | Outperform → Market Perform | Leerink Partners |
3/14/2024 | $9.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
3/14/2024 | Buy → Neutral | Ladenburg Thalmann | |
3/14/2024 | Buy → Neutral | H.C. Wainwright | |
2/21/2024 | $10.00 | Buy | Guggenheim |
3/8/2022 | $6.00 | Buy | Ladenburg Thalmann |
12/17/2021 | $15.00 | Outperform | Oppenheimer |
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
10-Q - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company's investor relations website for approximately 90 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focuse
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 4:30 p.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company's investor relations website for approximately 90 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company
Announced Strategic Collaboration with HMNC Brain Health GmbH (HMNC) to Develop Tildacerfont for the Treatment of Major Depressive Disorder (MDD) Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in Q4 2024 Topline Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH Anticipated in Q4 2024 Cash Runway Through the End of 2025 Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30
Oppenheimer analyst Hartaj Singh maintains Spruce Biosciences (NASDAQ:SPRB) with a Outperform and lowers the price target from $4 to $3.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.
Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. "Our goal with the POWER study is to ass
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company's Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. "On behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors," said Mike Grey, Executive Chairman of Spruce Biosciences. "Percival is an accomplished and
CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2 CAHptain Study in Pediatric Classic CAH Fully Enrolled Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates. "I am pleased by the meaningful pro
Guggenheim downgraded Spruce Biosciences from Buy to Neutral
Leerink Partners downgraded Spruce Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $9.00 previously
RBC Capital Mkts downgraded Spruce Biosciences from Outperform to Sector Perform and set a new price target of $2.00 from $9.00 previously
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosing Cohorts Topline Results from CAHmelia-204 Study of Tildacerfont in Adult Classic CAH Evaluating Glucocorticoid (GC) Reduction Anticipated in Third Quarter of 2024 Resource Prioritization and Cost Reductions Extend Cash Runway Through End of 2025 Conference Call Today at 4:30 p.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commerci